Pembrolizumab improves the prognosis for breast cancer regardless of age or menopausal status, according to new research.

Published Date: 20 Mar 2024

Recent findings from the phase 3 clinical trial KEYNOTE-756 demonstrate that patients, regardless of their immunotherapy status, have better outcomes when pembrolizumab is added to chemotherapy before and after breast cancer surgery.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Stem Cell Selection Unneeded for SSc Transplant Therapy?

2.

Lung Transplant for Lung Cancer: Promising, in Rare Cases

3.

Rural-urban disparities seen in cervical cancer

4.

Obesity linked to subsequent neoplasms in childhood cancer survivors

5.

New policy review highlights the importance of health-related quality of life in advanced cancer


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot